Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 178Endometrial Neoplasms 110Uterine Cervical Neoplasms 100Breast Neoplasms 58Colorectal Neoplasms 49Fallopian Tube Neoplasms 45Carcinoma, Non-Small-Cell Lung 42Neoplasms 36Pancreatic Neoplasms 34Prostatic Neoplasms 27Neoplasm Metastasis 27Stomach Neoplasms 25Melanoma 25Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 20Triple Negative Breast Neoplasms 19Carcinoma, Renal Cell 18Urinary Bladder Neoplasms 17Head and Neck Neoplasms 17Colonic Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma, Hepatocellular 15Small Cell Lung Carcinoma 14Sarcoma 14Cholangiocarcinoma 14Uterine Neoplasms 13Vulvar Neoplasms 12Rectal Neoplasms 12

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Gynecologic × 30 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡